HUMAN IGG4 FC POLYPEPTIDE VARIANT
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 6, 2015
filing date -
Oct 6, 2014
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed is a human IgG4 Fc polypeptide variant, including a modified CH2 domain of human IgG4 Fc, wherein the modification contains a replacement of a 6-20 consecutive amino acid sequence from the N-terminus of the CH2 domain of IgG4 with a 4-18 consecutive amino acid sequence from the N-terminus of human IgA1 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgA2 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgD CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgE CH2, or a 4-18 consecutive amino acid sequence from the N-terminus of human IgM CH2. The Fc variant imparts to a biologically active polypeptide—the modified Fc variant with a prolonged in-vivo half-life and reduced immunogenic reaction.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully